Immunic (IMUX) Competitors $0.83 -0.01 (-0.92%) Closing price 07/11/2025 04:00 PM EasternExtended Trading$0.84 +0.01 (+1.31%) As of 07/11/2025 07:27 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock IMUX vs. AVTE, TSVT, RCKT, ADCT, CRVS, TKNO, TNXP, FHTX, CMPS, and ANNXShould you be buying Immunic stock or one of its competitors? The main competitors of Immunic include Aerovate Therapeutics (AVTE), 2seventy bio (TSVT), Rocket Pharmaceuticals (RCKT), ADC Therapeutics (ADCT), Corvus Pharmaceuticals (CRVS), Alpha Teknova (TKNO), Tonix Pharmaceuticals (TNXP), Foghorn Therapeutics (FHTX), COMPASS Pathways (CMPS), and Annexon (ANNX). These companies are all part of the "pharmaceutical products" industry. Immunic vs. Its Competitors Aerovate Therapeutics 2seventy bio Rocket Pharmaceuticals ADC Therapeutics Corvus Pharmaceuticals Alpha Teknova Tonix Pharmaceuticals Foghorn Therapeutics COMPASS Pathways Annexon Aerovate Therapeutics (NASDAQ:AVTE) and Immunic (NASDAQ:IMUX) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, institutional ownership, profitability, media sentiment, risk, valuation and earnings. Which has more volatility & risk, AVTE or IMUX? Aerovate Therapeutics has a beta of 0.95, suggesting that its stock price is 5% less volatile than the S&P 500. Comparatively, Immunic has a beta of 1.49, suggesting that its stock price is 49% more volatile than the S&P 500. Is AVTE or IMUX more profitable? Aerovate Therapeutics' return on equity of -90.19% beat Immunic's return on equity.Company Net Margins Return on Equity Return on Assets Aerovate TherapeuticsN/A -90.19% -77.47% Immunic N/A -326.95%-181.34% Do institutionals & insiders have more ownership in AVTE or IMUX? 51.8% of Immunic shares are owned by institutional investors. 24.9% of Aerovate Therapeutics shares are owned by company insiders. Comparatively, 4.6% of Immunic shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth. Which has higher valuation & earnings, AVTE or IMUX? Aerovate Therapeutics is trading at a lower price-to-earnings ratio than Immunic, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAerovate TherapeuticsN/AN/A-$75.52M-$1.70-5.78ImmunicN/AN/A-$100.51M-$1.23-0.67 Do analysts prefer AVTE or IMUX? Immunic has a consensus price target of $11.60, suggesting a potential upside of 1,297.42%. Given Immunic's stronger consensus rating and higher probable upside, analysts clearly believe Immunic is more favorable than Aerovate Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Aerovate Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Immunic 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 2 Strong Buy rating(s) 3.25 Does the media refer more to AVTE or IMUX? In the previous week, Immunic had 4 more articles in the media than Aerovate Therapeutics. MarketBeat recorded 4 mentions for Immunic and 0 mentions for Aerovate Therapeutics. Immunic's average media sentiment score of 0.88 beat Aerovate Therapeutics' score of 0.00 indicating that Immunic is being referred to more favorably in the news media. Company Overall Sentiment Aerovate Therapeutics Neutral Immunic Positive SummaryImmunic beats Aerovate Therapeutics on 10 of the 14 factors compared between the two stocks. Get Immunic News Delivered to You Automatically Sign up to receive the latest news and ratings for IMUX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding IMUX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart IMUX vs. The Competition Export to ExcelMetricImmunicMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$79.54M$2.94B$5.55B$9.11BDividend YieldN/A2.42%5.07%4.01%P/E Ratio-0.6720.7128.2120.26Price / SalesN/A292.58431.9599.73Price / CashN/A42.1137.1257.67Price / Book4.157.638.045.49Net Income-$100.51M-$55.05M$3.19B$250.45M7 Day Performance13.87%8.43%3.63%4.79%1 Month Performance-1.64%5.42%4.06%7.68%1 Year Performance-39.85%2.03%30.02%16.44% Immunic Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)IMUXImmunic2.5531 of 5 stars$0.83-0.9%$11.60+1,297.4%-38.1%$79.54MN/A-0.6770AVTEAerovate TherapeuticsN/A$9.19-0.6%N/A-84.0%$266.37MN/A-3.0720High Trading VolumeTSVT2seventy bioN/A$5.00flat$5.00N/A$266.15M$48.37M-2.69440RCKTRocket Pharmaceuticals4.8652 of 5 stars$2.48-2.0%$18.60+650.0%-86.5%$264.83MN/A-0.94240Trending NewsADCTADC Therapeutics1.5396 of 5 stars$2.67-1.5%$7.75+190.3%-16.5%$264.81M$70.84M-1.84310News CoverageCRVSCorvus Pharmaceuticals2.8624 of 5 stars$3.88-0.3%$15.00+286.6%+109.1%$264.50MN/A-3.9630Positive NewsTKNOAlpha Teknova2.2532 of 5 stars$4.92-3.7%$8.50+72.8%+287.9%$262.93M$37.74M-10.25240Positive NewsTNXPTonix Pharmaceuticals2.6708 of 5 stars$35.60+2.0%$585.00+1,543.3%-33.1%$262.02M$10.09M-0.0250Trending NewsFHTXFoghorn Therapeutics1.9637 of 5 stars$4.70-2.9%$12.13+158.0%-8.0%$261.98M$22.60M-3.46120Positive NewsGap DownCMPSCOMPASS Pathways1.8573 of 5 stars$2.80+1.1%$17.00+507.1%-49.2%$261.97MN/A-1.41120ANNXAnnexon2.5538 of 5 stars$2.37-1.7%$12.50+427.4%-52.8%$260.01MN/A-2.0160News CoverageOptions VolumeGap Down Related Companies and Tools Related Companies Aerovate Therapeutics Alternatives 2seventy bio Alternatives Rocket Pharmaceuticals Alternatives ADC Therapeutics Alternatives Corvus Pharmaceuticals Alternatives Alpha Teknova Alternatives Tonix Pharmaceuticals Alternatives Foghorn Therapeutics Alternatives COMPASS Pathways Alternatives Annexon Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:IMUX) was last updated on 7/12/2025 by MarketBeat.com Staff From Our PartnersThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredI was wrong about TrumpI made a mistake. A mistake I feel very foolish about. After speaking with Donald Trump and some of his ...Porter & Company | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredA new rule goes live in July — and the banks are quietly cashing inA major change is quietly going into effect this July — and Wall Street is already positioning for it. Big ...American Alternative | SponsoredThe End of Elon Musk…?The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, an...Brownstone Research | SponsoredGold is soaring. Here’s how to get paid from itGold just broke through $3,300… And while the headlines shout about price targets, something even more powe...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Immunic, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Immunic With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
